An Investigational Immuno-therapy Study of BMS-986205 Combined With Nivolumab, Compared to Nivolumab by Itself, in Patients With Advanced Melanoma

For more information regarding Bristol-Myers Squibb Clinical Trial participation, please visit www.BMSStudyConnect.com Inclusion Criteria: * 12 years and older unless not permitted by local regulations; in that case 18 years old and older * Eastern Cooperative Oncology Group (ECOG) performance status of less than or equal to 1 * Histologically confirmed Stage III (unresectable) or Stage IV melanoma, per the American Joint Committee on Cancer (AJCC) Staging Manual (8th edition) * Treatment-naïve participants (no prior systemic anticancer therapy for unresectable or metastatic melanoma) * Measurable disease per RECIST v1.1 Exclusion Criteria: * Active brain metastases or leptomeningeal metastases * Uveal or ocular melanoma * Participants with active, known, or suspected autoimmune disease * Prior malignancy active within the previous 3 years except for locally curable cancers that have been apparently cured Other protocol defined inclusion/exclusion criteria could apply